一种里法米辛SV in situ凝制剂,用于治疗囊炎
Katia Mangano1, Cinzia Quatrocchi1, Katia Ajello1
1Cosmo SpA, Via C. Colombo 1, Lainate, 20045, MI, Italy.
Drug delivery and translational research
|February 13, 2025
概括
一种新的Rifamycin SV in situ凝,CB0125,有效地治疗炎,性结肠炎手术的并发症. 这种新配方在临床前模型中与现有治疗方法相比,显示出更高的疗效.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
背景情况:
- 炎是经过以囊袋门解剖为治疗性结肠炎的直肠切除术后的一种常见并发症.
- 一些囊炎病例具有抗生素耐药性,需要新的治疗方法.
- 利法西明显示有效性,但有针对性的输送系统可以改善结果.
研究的目的:
- 开发和评估CB0125,Rifamycin SV的新型局部凝配方,作为治疗毛囊炎的潜在疗法.
- 在大肠炎的临床前模型中评估CB0125的体内疗效和安全性.
主要方法:
- CB0125,Rifamycin SV配方,在生理条件下经历了溶液到凝的过渡.
- 在体内,有效性使用小鼠的德克斯硫酸诱导性结肠炎模型进行了测试.
- 评估了临床参数 (体重,出血,便一致性) 和组织病理学,并与梅沙和安慰剂进行了比较.
主要成果:
- 与安慰剂相比,CB0125耐受性良好,疾病活性显著降低.
- 现场凝配方的疗效优于梅萨拉胺和水中溶解的里法辛SV.
- 组织病理学分析显示,CB0125组的粘膜损伤和炎症减少.
结论:
- 里法米辛SV in situ凝 (CB0125) 显示出作为有效治疗囊炎的有希望的结果.
- 局部凝配方可能会增加炎症肠道粘膜的药物暴露,从而改善治疗效果.
- CB0125在治疗抗生素耐药性囊炎方面提供了潜在的进步.
相关概念视频
01:21Inflammatory Bowel Disease V: Surgical Management
95
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
95
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:29Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95
01:21Drugs for Treatment of Constipation-Predominant IBS
129
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
129